Veracyte, Inc. (VCYT) - Cash on Hand per Share

Corporate emblem and logo of veracyte.com (VCYT)

The cash per share of Veracyte, Inc. (VCYT) reflects the dynamics of a genomic analysis medical ecosystem deeply integrated into oncology centers, while 4.55 captures the current state of this parameter. The company's innovative tests eliminate unnecessary biopsies, optimizing costs for insurers. Expansion into European markets is driven by the strategic merger of acquired laboratories with organic business growth.

Veracyte (VCYT) - Cash per Share from 07/04/2022 to 11/20/2026

Analytical breakdowns for Veracyte Diagnostics (VCYT)

- market capitalization indicators:
- cash position and cash flow details:
General company analysis:Veracyte Corp, VCYT
Signature product of Veracyte Corp

For Veracyte, Inc. (VCYT), which develops high-tech genomic diagnostics and AI tests, the cash per share history reflects the ability to fund expansion without external borrowing. This indicator is calculated by dividing total liquid assets by the number of shares outstanding, determining the actual cash cushion per share and confirming the company's fundamental stability during periods of market volatility.